Assuntos
Diabetes Mellitus Tipo 2 , Hipoglicemiantes , Insulina , Lipodistrofia , Humanos , Masculino , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipertrofia/induzido quimicamente , Hipoglicemiantes/efeitos adversos , Hipoglicemiantes/uso terapêutico , Insulina/efeitos adversos , Insulina/uso terapêutico , Lipodistrofia/induzido quimicamente , IdosoRESUMO
OBJECTIVE: Cymbopogon citratus (DC.) Stapf is a medicinal and edible herb that is widely used for the treatment of gastric, nervous and hypertensive disorders. In this study, we investigated the cardioprotective effects and mechanisms of the essential oil, the main active ingredient of Cymbopogon citratus, on isoproterenol (ISO)-induced cardiomyocyte hypertrophy. METHODS: The compositions of Cymbopogon citratus essential oil (CCEO) were determined by gas chromatography-mass spectrometry. Cardiomyocytes were pretreated with 16.9 µg/L CCEO for 1 h followed by 10 µmol/L ISO for 24 h. Cardiac hypertrophy-related indicators and NLRP3 inflammasome expression were evaluated. Subsequently, transcriptome sequencing (RNA-seq) and target verification were used to further explore the underlying mechanism. RESULTS: Our results showed that the CCEO mainly included citronellal (45.66%), geraniol (23.32%), and citronellol (10.37%). CCEO inhibited ISO-induced increases in cell surface area and protein content, as well as the upregulation of fetal gene expression. Moreover, CCEO inhibited ISO-induced NLRP3 inflammasome expression, as evidenced by decreased lactate dehydrogenase content and downregulated mRNA levels of NLRP3, ASC, CASP1, GSDMD, and IL-1ß, as well as reduced protein levels of NLRP3, ASC, pro-caspase-1, caspase-1 (p20), GSDMD-FL, GSDMD-N, and pro-IL-1ß. The RNA-seq results showed that CCEO inhibited the increase in the mRNA levels of 26 oxidative phosphorylation complex subunits in ISO-treated cardiomyocytes. Our further experiments confirmed that CCEO suppressed ISO-induced upregulation of mt-Nd1, Sdhd, mt-Cytb, Uqcrq, and mt-Atp6 but had no obvious effects on mt-Col expression. CONCLUSION: CCEO inhibits ISO-induced cardiomyocyte hypertrophy through the suppression of NLRP3 inflammasome expression and the regulation of several oxidative phosphorylation complex subunits.
Assuntos
Cymbopogon , Óleos Voláteis , Óleos Voláteis/farmacologia , Inflamassomos/metabolismo , Proteína 3 que Contém Domínio de Pirina da Família NLR , Cymbopogon/química , Cymbopogon/metabolismo , Isoproterenol , Miócitos Cardíacos/metabolismo , Fosforilação Oxidativa , RNA Mensageiro/metabolismo , Hipertrofia/induzido quimicamente , Hipertrofia/tratamento farmacológico , Hipertrofia/metabolismoRESUMO
Zearalenone (ZEN), a non-steroidal Fusarium graminearum with an estrogen effect, can cause damage to the gastrointestinal tract, immune organs, liver, and reproductive system. Further analysis of the mechanism of ZEN has become an important scientific issue. We have established in vivo and in vitro models of ZEN intervention, used AMPK/mTOR as a targeted pathway for ZEN reproductive toxicity, and explored the molecular mechanism by which ZEN may induce uterine hypertrophy in weaned piglets. Our study strongly suggested that ZEN can activate the phosphorylation of AMPK in uterine endometrial epithelium cells, affect the phosphorylation level of mTOR through TSC2 and Rheb, induce autophagy, upregulate the expression of proliferative genes PCNA and BCL2, downregulate the expression of apoptotic gene BAX, promote uterine endometrial epithelium cells proliferation, and ultimately lead to thickening of the endometrial and myometrium, increased density of uterine glands, and induce uterine hypertrophy.
Assuntos
Zearalenona , Feminino , Animais , Suínos , Zearalenona/metabolismo , Proteínas Quinases Ativadas por AMP , Serina-Treonina Quinases TOR , Autofagia , Hipertrofia/induzido quimicamenteRESUMO
OBJECTIVES: Dyschromia is an understudied aspect of hypertrophic scar (HTS). The use of topical tacrolimus has successfully shown repigmentation in vitiligo patients through promotion of melanogenesis and melanocyte proliferation. It was hypothesized that HTSs treated with topical tacrolimus would have increased repigmentation compared to controls. METHODOLOGY: Full-thickness burns in red Duroc pigs were either treated with excision and meshed split-thickness skin grafting or excision and no grafting, and these wounds formed hypopigmented HTSs (n = 8). Half of the scars had 0.1% tacrolimus ointment applied to the scar twice a day for 21 days, while controls had no treatment. Further, each scar was bisected with half incurring fractional ablative CO2 laser treatment before topical tacrolimus application to induce laser-assisted drug delivery (LADD). Pigmentation was evaluated using a noninvasive probe to measure melanin index (MI) at Days 0 (pretreatment), 7, 14, and 21. At each timepoint, punch biopsies were obtained and fixed in formalin or were incubated in dispase. The formalin-fixed biopsies were used to evaluate melanin levels by H&E staining. The biopsies incubated in dispase were used to obtain epidermal sheets. The ESs were then flash frozen and RNA was isolated from them and used in quantitative reverse transcription polymerase chain reaction for melanogenesis-related genes: Tyrosinase (TYR), TYR-related protein-1 (TYRP1), and dopachrome tautomerase (DCT). Analysis of variance test with Sídák's multiple comparisons test was used to compare groups. RESULTS: Over time, within the grafted HTS and the NS group, there were no significant changes in MI, except for Week 3 in the -Tacro group. (+Tacro HTS= pre = 685.1 ± 42.0, w1 = 741.0 ± 54.16, w2 = 750.8 ± 59.0, w3 = 760.9 ± 49.8) (-Tacro HTS= pre = 700.4 ± 54.3, w1 = 722.3 ± 50.7, w2 = 739.6 ± 53.2, w3 = 722.7 ± 50.5). Over time, within the ungrafted HTS and the NS group, there were no significant changes in MI. (+Tacro HTS= pre = 644.9 ± 6.9, w1 = 661.6 ± 3.3, w2 = 650.3 ± 6.2, w3 = 636.3 ± 7.4) (-Tacro HTS= pre = 696.8 ± 8.0, w1 = 695.8 ± 12.3, w2 = 678.9 ± 14.0, w3 = 731.2 ± 50.3). LADD did not lead to any differential change in pigmentation compared to the non-LADD group. There was no evidence of increased melanogenesis within the tissue punch biopsies at any timepoint. There were no changes in TYR, TYRP1, or DCT gene expression after treatment. CONCLUSION: Hypopigmented HTSs treated with 0.1% tacrolimus ointment with or without LADD did not show significantly increased repigmentation. This study was limited by a shorter treatment interval than what is known to be required in vitiligo patients for repigmentation. The use of noninvasive, topical treatments to promote repigmentation are an appealing strategy to relieve morbidity associated with dyschromic burn scars and requires further investigation.
Assuntos
Queimaduras , Cicatriz Hipertrófica , Hipopigmentação , Vitiligo , Animais , Humanos , Suínos , Tacrolimo/uso terapêutico , Cicatriz Hipertrófica/tratamento farmacológico , Cicatriz Hipertrófica/etiologia , Vitiligo/tratamento farmacológico , Pomadas/uso terapêutico , Melaninas/uso terapêutico , Hipopigmentação/tratamento farmacológico , Hipopigmentação/etiologia , Hipertrofia/induzido quimicamente , Hipertrofia/complicações , Hipertrofia/tratamento farmacológico , Queimaduras/complicações , Formaldeído/uso terapêutico , Resultado do TratamentoRESUMO
Abstract Background: Pioglitazone has been widely used as an insulin-sensitizing agent for improving glycemic control in patients with type 2 diabetes mellitus. However, cardiovascular risk and protective effects of pioglitazone remain controversial. Objectives: In this study, we investigated whether pioglitazone affects cardiomyocyte apoptosis and hypertrophy by regulating the VEGFR-2 signaling pathway. Methods: Cardiomyocytes were enzymatically isolated from 1- to 3-day-old Sprague-Dawley rat ventricles. Effects of pioglitazone and the VEGFR-2-selective inhibitor apatinib on cardiomyocyte apoptotic rate was determined using flow cytometry, and hypertrophy was evaluated using [3H]-leucine incorporation. The protein expressions of unphosphorylated and phosphorylated VEGFR-2, Akt, P53, and mTOR were determined by Western-Blotting. Analysis of variance (ANOVA) was used to assess the differences between groups. Results: Pioglitazone and VEGFR-2-selective inhibitor apatinib reduced rat cardiomyocyte viability and cardiomyocyte hypertrophy induced by angiotensin II in vitro. Furthermore, in the same in vitro model, pioglitazone and apatinib significantly increased the expression of Bax and phosphorylated P53 and decreased the expression of phosphorylated VEGFR-2, Akt, and mTOR, which promote cardiomyocyte hypertrophy. Conclusions: These findings indicate that pioglitazone induces cardiomyocyte apoptosis and inhibits cardiomyocyte hypertrophy by modulating the VEGFR-2 signaling pathway.
Resumo Fundamento: A pioglitazona tem sido amplamente utilizada como droga sensibilizadora da insulina para melhorar o controle glicêmico em pacientes com diabetes mellitus tipo 2. No entanto, o risco cardiovascular bem como os efeitos protetores da pioglitazona ainda são controversos. Objetivos: Neste estudo, investigamos se os efeitos da pioglitazona sobre a apoptose e a hipertrofia de cardiomiócitos ocorrem via regulação da via de sinalização do VEGFR-2. Métodos: os cardiomiócitos foram isolados enzimaticamente dos ventrículos de ratos Sprague-Dawley de 1-3 anos de vida. Os efeitos da pioglitazona e do inibidor seletivo de VEGFR-2 apatinib sobre a taxa de apoptose dos cardiomiócitos foram avaliados por citometria de fluxo, e a hipertrofia avaliada por incorporação de leucina-[3H]. As expressões de VEGFR-2, Akt, P53, e mTOR fosforiladas e não fosforiladas foram determinadas por Western Blotting. Análise de variância (ANOVA) foi usada para avaliar diferenças entre os grupos. Resultados: a pioglitazona e o apatinib reduziram a viabilidade e a hipertrofia de cardiomiócitos induzida por angiotensina II in vitro. Além disso, no mesmo modelo in vitro, a pioglitazona e o apatinib aumentaram significativamente a expressão de Bax e P53 fosforilada, e diminuiu a expressão de VEGFR-2, Akt, e mTOR, que promove hipertrofia de cardiomiócitos. Conclusões: Esses resultados indicam que a pioglitazona induz a apoptose e inibe a hipertrofia de cardiomiócitos pela modulação da via de sinalização de VEGFR-2.
Assuntos
Animais , Ratos , Apoptose/efeitos dos fármacos , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/efeitos dos fármacos , Tiazolidinedionas/farmacologia , Hipoglicemiantes/farmacologia , Transdução de Sinais/efeitos dos fármacos , Ratos Sprague-Dawley , Miócitos Cardíacos/efeitos dos fármacos , Miócitos Cardíacos/patologia , Pioglitazona , Hipertrofia/induzido quimicamente , Hipertrofia/patologia , Animais Recém-NascidosRESUMO
Angiotensin II (Ang II) plays an important role in cardiomyocyte hypertrophy. The combined effect of hepatocyte growth factor (HGF) and Ang II on cardiomyocytes is unknown. The present study was designed to determine the effect of HGF on cardiomyocyte hypertrophy and to explore the combined effect of HGF and Ang II on cardiomyocyte hypertrophy. Primary cardiomyocytes were isolated from neonatal rat hearts and cultured in vitro. Cells were treated with Ang II (1 µM) alone, HGF (10 ng/mL) alone, and Ang II (1 µM) plus HGF (10 ng/mL) for 24, 48, and 72 h. The amount of [³H]-leucine incorporation was then measured to evaluate protein synthesis. The mRNA levels of β-myosin heavy chain and atrial natriuretic factor were determined by real-time PCR to evaluate the presence of fetal phenotypes of gene expression. The cell size of cardiomyocytes was also studied. Ang II (1 µM) increased cardiomyocyte hypertrophy. Similar to Ang II, treatment with 1 µM HGF promoted cardiomyocyte hypertrophy. Moreover, the combination of 1 µM Ang II and 10 ng/mL HGF clearly induced a combined pro-hypertrophy effect on cardiomyocytes. The present study demonstrates for the first time a novel, combined effect of HGF and Ang II in promoting cardiomyocyte hypertrophy.
Assuntos
Animais , Ratos , Angiotensina II/farmacologia , Fator de Crescimento de Hepatócito/farmacologia , Miócitos Cardíacos/efeitos dos fármacos , Animais Recém-Nascidos , Células Cultivadas , Relação Dose-Resposta a Droga , Hipertrofia/induzido quimicamente , Hipertrofia/patologia , Miócitos Cardíacos/patologia , Ratos Sprague-Dawley , Reação em Cadeia da Polimerase em Tempo Real , RNA Mensageiro/genética , RNA Mensageiro/metabolismoRESUMO
Os esteróides anabólicos androgênicos (EAA) são compostos formados a partir da testosterona ou um de seus derivados, sendo amplamente utilizados por desportistas amadores e profissionais com o objetivo de melhorar a performance atlética. Entretanto, a literatura a respeito da relação entre EAA e hipertrofia muscular é controversa. O objetivo deste estudo foi avaliar os efeitos da nandrolona e do treinamento físico sobre a hipertrofia muscular. Ratos Wistar machos receberam injeção i.m. de Deca-Durabolin® ou veículo durante 6 semanas. Os animais dos grupos treinados foram submetidos a treinamento físico resistido, através de sessões de saltos em meio líquido. Os animais sedentários e treinados foram sacrificados após anestesia e o músculo sóleo retirado para quantificação de proteínas totais e DNA. Ao final do tratamento, os animais treinados tratados com veículo ou EAA apresentaram menor peso corporal do que os respectivos grupos sedentários. Não foram observadas diferenças estatísticas na concentração de proteínas totais e na razão peso muscular/peso corporal entre os grupos experimentais. O grupo treinado tratado com EAA apresentou concentração de DNA significativamente menor do que o grupo treinado veículo. A administração de decanoato de nandrolona não promoveu hipertrofia do músculo sóleo, nem mesmo quando associada ao treinamento físico resistido.
Assuntos
Animais , Masculino , Ratos , Anabolizantes/administração & dosagem , Músculo Esquelético/efeitos dos fármacos , Nandrolona/análogos & derivados , Condicionamento Físico Animal/fisiologia , Análise de Variância , Modelos Animais de Doenças , Hipertrofia/induzido quimicamente , Músculo Esquelético/química , Músculo Esquelético/patologia , Nandrolona/administração & dosagem , Ratos WistarRESUMO
Estudos em animais demonstram que a acidose metabólica promove muitas mudanças morfológicas e bioquímicas nos rins, que estão intimamente associadas com a hipertrofia do órgão Confirmamos que a acidose metabólica crónica causada pela ingestão de cloreto de amónia (NH4Cl), promove a hipertrofia do órgão e também uma diminuição da reabsorção de água e sais pelos rins. Aventamos a hipótese que esses são processos que competem pela energia disponível pelas células tubulares Como a mitocòndria tem sido implicada em uma variedade de processos metabólicos, nós estudamos o comportamento das mitocôndrias isoladas de rins de ratos tratados com NH4Cl As mitocôndrias de rim de ratos (MRR) acidóticos apresentaram uma diminuição de aproximadamente 25% da eficiência da respiração, através do controle respiratório Usando o mesmo substrato (succinato), nós achamos a relação ADP/O significativamente menor nos animais acidóticos quando comparados aos controles Em concordância com esses resultados, o potencial transmembrana mitocondrial, apresentou o tempo de fosforilação aumentado nesses animais, determinado pelo método da safranina. Nenhuma diferença significativa foi observada no potencial em ambas as mitocôndrias. Interessantemente, na determinação do transporte de cálcio, verificamos uma captação inicial mais rápida e maior nas MRR acidóticos, quando comparadas aos controles, mantida equilibrada por mais tempo com a adição do inibidor do poro de transição de permeabilidade mitocondrial, a ciclosporina A (CsA). Não foi observada nenhuma diferença significativa na liberação do cálcio após adição de vermelho de Rutênio (RR) e cloreto de ...
Studies in animals have shown that metabolic acidosis causes several morphologic and biochemical changes in kidney, which are ultimately associated with organ hypertrophy We have previously shown that chronic metabolic acidosis caused by feeding NH4Cl lead to nephron hypertrophy and to a decreased water-salt reabsortion by the kidneys Since mitochondria have been implicated in a variety of metabolic disorders, we examined energy linked functions in isolated mitochondria from rat kidneys with chronic metabolic acidosis induced by NH4Cl Mitochondria from acidotic rats presented resting respiration supported by succinate oxidation 25% slower when compared to control mitochondria Using the same substrate we found an ADP/O ratio of 1,4 in control and 1,1 in isolated mitochondria from acidotic rats. Accordingly, the transient decrease in ?? that occurs during ADP phosphorylation was much larger in mitochondria from acidotic rat kidneys as evidenced by the safranine method No significant difference in ?? could be detected in both types of mitochondria using this method. Interestingly, determination of Ca2+ transport showed a faster rate of initial Ca2+ up take by mitochondria from acidotics and a lower concentration of extramitochondrial Ca2+ under steady state conditions...